TILT Biotherapeutics: Funding, Investors & Team (Sep 2026)
Slant Biotherapeutics is the main organization universally working in the space of empowering growth T-cell treatment with oncolytic infections. Slant is a preclinical stage organization working in the field of disease immunotherapy and will before long make an interpretation of its remarkable methodology into clinical preliminaries. The organization's protected innovation includes usage of oncolytic infections for improvement of growth T-cell treatment. Introductory exemplifications of the innovation will be utilized to improve growth penetrating lymphocyte (TIL), fanciful antigen receptor (CAR-T) and designated spot repressing immunizer treatment. The TILT approach can possibly accomplish comparative outcomes in CAR-T treatment of strong growths as right now accomplished for CD19+ hematological growths.
TILT Biotherapeutics has raised $48.4M across 4 funding rounds on record, the most recent a Series B of $25.3M announced in May 2025.
That round is above the $4.1M median round size for Apps companies tracked on FundedIQ over the last two years.
TILT Biotherapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
TILT Biotherapeutics Funding Rounds
TILT Biotherapeutics raised $10.5M in an undisclosed round announced in Jun 2022.
8 months later, an undisclosed round of $10.6M was announced in Feb 2023.
1 years later, an undisclosed round of $2.0M was announced in Feb 2024.
1.3 years later, a Series B of $25.3M was announced in May 2025.
TILT Biotherapeutics Founders and Leadership Team
Contact details for the TILT Biotherapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →TILT Biotherapeutics Funding Compared to Other Apps Startups
TILT Biotherapeutics' latest round of $25.3M is above the median round in Apps. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TILT Biotherapeutics in Apps and Helsinki
Companies Similar to TILT Biotherapeutics
Ferrivia Oy is a Finnish health-tech startup specializes in digital health services and personalized tracking…
Oura is a pioneering sleep performance platform, focused on improving sleep that leads to a better life. The…
Coiniverse is a comprehensive app for collecting coins, suitable for both seasoned collectors and beginners…
Perfat Technologies is a technology company focused on health that creates applications for managing fats…
Smart Mobility Platform business providing connection even when before was none
Crafting Stellar Puzzle Games
VIRTA offers a complete turnkey solution for managing electric vehicle charging services of any scale. Our…
Hintsa is the world's driving, proof based training organization, assisting top competitors and business…
Quicksave Interactive is a chat game platform developing fun gaming-based chatting applications. It is on a…
MaaS Global is the Mobility-as-a-Service operator, is set to change how people move in the future. As the…
Veri helps health-conscious individuals achieve optimal metabolic health through a blood sugar sensor and an…
BuddyCare is a mobile care coordination platform that automates patient pathway coordination, allowing…
TILT Biotherapeutics Funding FAQs
What does TILT Biotherapeutics do?
Slant Biotherapeutics is the main organization universally working in the space of empowering growth T-cell treatment with oncolytic infections. Slant is a preclinical stage organization working in the field of disease immunotherapy and will before long make an interpretation of its remarkable methodology into clinical preliminaries. The organization's protected innovation includes usage of oncolytic infections for improvement of growth T-cell treatment. Introductory exemplifications of the innovation will be utilized to improve growth penetrating lymphocyte (TIL), fanciful antigen receptor (CAR-T) and designated spot repressing immunizer treatment. The TILT approach can possibly accomplish comparative outcomes in CAR-T treatment of strong growths as right now accomplished for CD19+ hematological growths.
How much funding has TILT Biotherapeutics raised?
TILT Biotherapeutics has raised $48.4M across 4 rounds on record. The most recent is a Series B of $25.3M announced in May 2025.
When did TILT Biotherapeutics last raise funding?
TILT Biotherapeutics' most recent funding round on record is a Series B of $25.3M, announced in May 2025.
Who founded TILT Biotherapeutics?
FundedIQ lists Akseli Hemminki (Founder) at TILT Biotherapeutics.
Where is TILT Biotherapeutics headquartered?
TILT Biotherapeutics is based in Helsinki, Southern Finland, Finland.
How many employees does TILT Biotherapeutics have?
TILT Biotherapeutics is in the 11-50 employee band.
How does TILT Biotherapeutics' funding compare to other Apps startups?
TILT Biotherapeutics' latest round of $25.3M is above the $4.1M median round size for Apps companies on FundedIQ across 2,426 tracked companies over the last two years.
About FundedIQ's TILT Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TILT Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.